Vanderbilt University

Katrina A Bollinger

Craig William Lindsley

P Jeffrey Conn

Darren W Engers

Julie L Engers

Kyle A Emmitte

Andrew S Felts

Sean R Bollinger

Paul K Spearing

Rory A Capstick

Anna L Blobaum

Jerri M Rook

Megan M Breiner

PJeffrey Conn

Described are positive allosteric modulators of muscarinic acetylcholine receptor M(mAChR M), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.

Positive allosteric modulators of the muscarinic acetylcholine receptor M

Disclosed herein are pyrido[3',2&#x2032;:4,5]thieno[3,2-d]pyrimidine and pyrimido[4&#x2032;,5&#x2032;:4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Positive allosteric modulators of the muscarinic acetylcholine receptor M1

4,5-Substituted Picolinamide and picolinonitrile compounds of formula (I), where Ris CONHor CN and Ris an optionally substituted aryl or heteroaryl, are negative allosteric modulators of the metabotropic glutamate receptor 2 (mGlu). The compounds and pharmaceutical compositions including the compounds may be useful for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject. 

4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators

Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu3), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, cognitive disorders, schizophrenia, Alzheimer's disease, or cancer in a subject.

Negative allosteric modulators of metabotropic glutamate receptor 3

Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

Negative allosteric modulators of metabotropic glutamate receptor 2

Growing community of inventors

Murfreesboro, TN, United States of America

Katrina A Bollinger